Herein, we have comprehensively characterized GBA1 in a sample from the Norwegian population by (1) employing and evaluating Oxford Nanopore sequencing as a strategy, (2) determining the frequency of variants within the GBA1 gene in patients with PD and healthy controls by providing an update on previous reports [12, 17], and (3) reviewing current literature on newly identified variants that add to pathogenicity determination. Here, GBA1 is linked to Parkinson disease.